Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again - MarketWatch
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - XM
Sage Therapeutics’ stock slides after trial of Huntington’s Disease treatment fails and company says it will end it - MarketWatch
Sage Therapeutics’ stock slides after trial of Huntington’s Disease treatment fails and company says it will end it - MarketWatch
Sage Therapeutics' rare disease drug fails mid-stage study - XM
SAGE Therapeutics (SAGE) Reports Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor - StreetInsider.com
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease - Business Wire
Sage Therapeutics' stock falls after therapy fails for a third time - MarketWatch
Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial | SAGE Stock News - StockTitan
Sage to abandon development of neurological disorder drug after multiple failures - Reuters

Pages